Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.61 |
| ▸ | HPGD | P15428 | 5/20 | 0.61 |
| ▸ | MEN1 | O00255 | 4/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.61 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.61 |
| ▸ | ESR1 | P03372 | 2/20 | 0.56 |
| ▸ | SHBG | P04278 | 1/20 | 0.56 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 6/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 5/20 | 0.54 |
| ▸ | SLC5A1 | P13866 | 3/20 | 0.54 |
| ▸ | SLC5A2 | P31639 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.54 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.54 |
| ▸ | ATM | Q13315 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5036945 | 0.88 | MAPT (0.77) | MAPTHPGDMEN1KMT2ACYP3A4 | |
| SCHEMBL11627675 | 0.83 | SLC5A1 (0.71) | MAPTHPGDMEN1KMT2ACYP3A4 | |
| SCHEMBL5622899 | 0.80 | MAPT (0.71) | MAPTHPGDMEN1KMT2ACYP3A4 | |
| SCHEMBL13991130 | 0.80 | LMNA (0.79) | MAPTHPGDMEN1KMT2ACYP3A4 | |
| SCHEMBL5623783 | 0.77 | NFKB1 (0.61) | MAPTHPGDMEN1KMT2ACYP3A4 | |
| SCHEMBL6396380 | 0.76 | MAPT (0.56) | MAPTHPGDMEN1KMT2ACYP3A4 | |
| SCHEMBL6402624 | 0.76 | HPGD (0.52) | MAPTHPGDMEN1KMT2ACYP3A4 | |
| SCHEMBL11628971 | 0.76 | SLC5A1 (0.71) | MAPTHPGDMEN1KMT2ACYP3A4 | |
| SCHEMBL145265 | 0.75 | LMNA (0.78) | MAPTHPGDMEN1KMT2ACYP3A4 | |
| SCHEMBL1500125 | 0.75 | CYP3A4 (0.74) | MAPTHPGDMEN1KMT2ACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170362210-A1 | ANTI-ESTROGENIC COMPOUNDS | PFIZER INC. (US) | 2017-12-21 | — | — | US | disclosed |
| US-20170362210-A1 | ANTI-ESTROGENIC COMPOUNDS | PFIZER INC. (US) | 2017-12-21 | — | — | US | disclosed |
| US-20170362210-A1 | ANTI-ESTROGENIC COMPOUNDS | PFIZER INC. (US) | 2017-12-21 | — | — | US | disclosed |
| WO-2016174551-A1 | ANTI-ESTROGENIC COMPOUNDS | PFIZER INC. (US) | 2016-11-03 | — | — | WO | disclosed |
| WO-2016174551-A1 | ANTI-ESTROGENIC COMPOUNDS | PFIZER INC. (US) | 2016-11-03 | — | — | WO | disclosed |
| US-20160311805-A1 | ANTI-ESTROGENIC COMPOUNDS | PFIZER INC. (US) | 2016-10-27 | — | — | US | disclosed |
| US-20160311805-A1 | ANTI-ESTROGENIC COMPOUNDS | PFIZER INC. (US) | 2016-10-27 | — | — | US | disclosed |
| US-20160311805-A1 | ANTI-ESTROGENIC COMPOUNDS | PFIZER INC. (US) | 2016-10-27 | — | — | US | disclosed |
| US-20150197506-A1 | NOVEL BENZOPYRAN COMPOUNDS, COMPOSITIONS AND USES THEREOF | OLEMA PHARMACEUTICALS, INC. (US) | 2015-07-16 | — | — | US | disclosed |
| US-20150197506-A1 | NOVEL BENZOPYRAN COMPOUNDS, COMPOSITIONS AND USES THEREOF | OLEMA PHARMACEUTICALS, INC. (US) | 2015-07-16 | — | — | US | disclosed |
| US-9018244-B2 | Benzopyran compounds, compositions and uses thereof | OLEMA PHARMACEUTICALS, INC. (US) | 2015-04-28 | — | — | US | disclosed |
| US-9018244-B2 | Benzopyran compounds, compositions and uses thereof | OLEMA PHARMACEUTICALS, INC. (US) | 2015-04-28 | — | — | US | disclosed |
| US-20130178445-A1 | Novel Benzopyran Compounds, Compositions and Uses Thereof | OLEMA PHARMACEUTICALS, INC. (US) | 2013-07-11 | — | — | US | disclosed |
| US-20130178445-A1 | Novel Benzopyran Compounds, Compositions and Uses Thereof | OLEMA PHARMACEUTICALS, INC. (US) | 2013-07-11 | — | — | US | disclosed |
| WO-2013090921-A1 | NOVEL BENZOPYRAN COMPOUNDS, COMPOSITIONS AND USES THEREOF | OLEMA PHARMACEUTICALS, INC. (US) | 2013-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150197506-A1 | NOVEL BENZOPYRAN COMPOUNDS, COMPOSITIONS AND USES THEREOF | ESR2, GPER1, ESR1 | MAPT 3454/4885HPGD 1227/4885MEN1 4303/4885 |
| US-20130178445-A1 | Novel Benzopyran Compounds, Compositions and Uses Thereof | ESR2, GPER1, ESR1 | MAPT 3454/4885HPGD 1227/4885MEN1 4303/4885 |
| US-20170362210-A1 | ANTI-ESTROGENIC COMPOUNDS | ESR1, ESRRA, ESR2 | MAPT 4628/4885HPGD 2014/4885MEN1 631/4885 |
| US-20160311805-A1 | ANTI-ESTROGENIC COMPOUNDS | ESR1, ESRRA, ESR2 | MAPT 4628/4885HPGD 2014/4885MEN1 631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.